Retinopathy of prematurity: Current concepts in molecular pathogenesis

Seminars in Ophthalmology

Volumn 24, Issue 2, 2009, Pages 77-81

  Heidary, Gena ^a   Vanderveen, Deborah ^a   Smith, Lois E ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Erythropoietin; IGF 1; Neovascularization; Polyunsaturated Omega 3 Fatty Acids; Prematurity; Retinopathy; VEGF

Indexed keywords

ERYTHROPOIETIN; OMEGA 3 FATTY ACID; SOMATOMEDIN C; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; DIET SUPPLEMENTATION; DISEASE COURSE; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA BLOOD VESSEL; RETROLENTAL FIBROPLASIA; REVIEW; ANIMAL; ANOXIA; FEMALE; FETOMATERNAL TRANSFUSION; METABOLISM; NEWBORN; OPHTHALMOLOGY; PREGNANCY;

ANIMALS; ANOXIA; ERYTHROPOIETIN; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; INFANT, NEWBORN; INSULIN-LIKE GROWTH FACTOR I; MATERNAL-FETAL EXCHANGE; OPHTHALMOLOGY; PREGNANCY; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 66149151045     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530902800314     Document Type: Review

References (42)

1. Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. Am. J. Ophthalmol. 1942;25:203-204.
2. Gilbert C, Foster A. Childhood blindness in the context of VISION 2020-the right to sight. Bull. World Health Organ 2001;79:227-232.
3. Gilbert C, Muhit M. Twenty years of childhood blindness: What have we learnt? Community Eye Health 2008;21:46-47.
4. Gilbert C, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: Implications for screening programs. Pediatrics 2005;115:e518-e525.
5. Cryotherapy for retinopathy of prematurity cooperative group. Multicenter trial of cryotherapy for retinopathy of prematurity: Preliminary results. Archives of Ophthalmology 1988;106:471- 479.
6. Shalev B, Farr AK, Repka MX. Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: Seven-year outcome. Am. J. Ophthalmol. 2001;132:76-80.
7. Tasman W. Ten-year follow-up from the CRYO-ROP study. Arch. Ophthalmol. 2001;119:1200-1201.
8. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans. Ophthalmol. Soc. U. K. 1948;68:137-180.
9. Ashton N, Ward B, Serpell G. Effect of oxygen of developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br. J. Ophthalmol. 1954;38:397-432.
10. Roth AM. Retinal vascular development in premature infants. Am. J. Ophthalmol. 1977;84:636-640.
11. Hughes S,Yang H,Chan-Ling T. Vascularizationof the human fetal retina: Roles of vasculogenesis and angiogenesis. Invest Ophthalmol. Vis. Sci. 2000;41:1217-1228.
12. Chan-Ling T, et al. Astrocyte-endothelial cell relationships during human retinal vascular development. Invest Ophthalmol. Vis. Sci. 2004;45:2020-2032.
13. Lutty GA, et al. Proceedings of the Third International Symposium on Retinopathy of Prematurity: An update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol. Vis. 2006;12:532-580.
14. Patz A. Clinical and experimental studies on retinal neovascu-larization. Am. J. Ophthalmol. 1982;94:715-743.
15. Chan-Ling T, Gock B, Stone J. The effect of oxygen on vasoformative cell division. Evidence that 'physiological hypoxia' is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol. Vis. Sci. 1995;36:1201-1214.
16. Smith LE. Through the eyes of a child: Understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol. Vis. Sci. 2008;49:5177-5182.
17. Madan A, Penn JS. Animal models of oxygen-induced retinopathy. Front Biosci. 2003;8:d1030-d1043.
18. Smith LE, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol. Vis. Sci. 1994;35:101-111.
19. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
20. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
21. Penn JS, et al. Vascular endothelial growth factor in eye disease. Prog. Retin. Eye Res. 2008;27:331-371.
22. Stone J, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J. Neurosci. 1995;15:4738-4747.
23. Pierce EA, Foley ED, Smith LE. Regulation ofvascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch. Ophthalmol. 1996;114:1219-1228.
24. Shih SC, Ju M, Liu N, Smith LE. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J. Clin. Invest 2003;112:50-57.
25. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. U. S. A. 1995;92:905-909.
26. Robinson GS, et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc. Natl. Acad. Sci. U. S. A. 1996;93:4851-4856.
27. Jiang J, et al. Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF. J. Cell Physiol 2009;218:66-74.
28. Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin as an angiogenic factor. Eur. J. Clin. Invest 2003;33:891-896.
29. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc. Res. 2002;64:326-333.
30. Morita M, et al. HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 2003;22:1134-1146.
31. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J. Clin. Invest 2008;118:526-533.
32. Chen J, et al. Erythropoietin siRNA suppresses retinal neovascularization in a mouse model of proliferative retinopathy. Invest Ophthalmol. Vis. Sci. 2008.
33. Suk KK, et al. Human recombinant erythropoietin and the incidence of retinopathy of prematurity: A multiple regression model. J. AAPOS. 2008;12:233-238.
34. Chen J, Smith LE. A double-edged sword: Erythropoietin eyed in retinopathy of prematurity. J. AAPOS. 2008;12:221-222.
35. Langford K, Nicolaides K, Miell JP. Maternal and fetal insulinlike growth factors and their binding proteins in the second and third trimesters of human pregnancy. Human Reproduction 1998;13:1389-1393.
36. Hellstrom A, et al. IGF-I is critical for normal vascularization of the human retina. J. Clin. Endocrinol. Metab 2002;87:3413-3416.
37. Hellstrom A, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity. Proc. Natl. Acad. Sci. U. S. A 2001;98:5804-5808.
38. Smith LE, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997;276:1706- 1709.
39. Smith LE, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat. Med. 1999;5:1390-1395.
40. Mukherjee PK, Chawla A, Loayza MS, Bazan NG. Docosanoids are multifunctional regulators of neural cell integrity and fate: Significance in aging and disease. Prostaglandins Leukot. Essent. Fatty Acids 2007;77:233-238.
41. Lukiw WJ, Bazan NG. Docosahexaenoic acid and the aging brain. J. Nutr. 2008;138:2510-2514.
42. Connor KM, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med. 2007;13:868-873.